2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Neonatal, Young Adult
PAPER

4787 Orelabrutinib-based therapy for refractory immune thrombocytopenia: A real-world retrospective study of efficacy and safety

Wanying Lin, Ye Jieyu2
1 Nanfang Hospital of Southern Medical University, Guangzhou, China
2 Nanfang Hospital of Southern Medical University, Guangzhou, China

Introduction

Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated platelet destruction and impaired platelet production. Orelabrutinib, a BTK inhibitor, not only interferes with B-cell activation and antibody generation but also modulates macrophage function, blocks Fcγ receptor signaling, and thereby reduces platelet destruction. In a phase 2 study of orelabrutinib for ITP, the overall response rate (ORR) was 40%, the median time to response (TTR) was 9 days, and the 6-month sustained response rate (SRR) was 30%. Notably, among patients who had previously responded to corticosteroids or IVIg, the ORR was 75%. Based on these findings, we conducted a retrospective analysis to evaluate the efficacy and safety of an orelabrutinib-containing regimen in the real-world treatment of ITP.

Methods

This single-arm, retrospective study enrolled patients aged 18–75 years with primary ITP lasting >12 months. Eligibility required an ECOG performance status of 0–1 and either refractory disease or relapse following at least one prior therapy. Participants received oral orelabrutinib 50 mg once daily for a minimum of 4 weeks. The primary endpoints were OR (platelet count ≥30 × 10?/L and at least doubling from baseline, with no bleeding) and CR (platelet count ≥100 × 10?/L with no bleeding). The secondary endpoint was sustained response, defined as maintenance of response for ≥ 6 months after treatment initiation. Early efficacy was assessed at week 4, while final response was determined by comparing the platelet count at treatment discontinuation or last visit against baseline values.

Results

From July 2022 to January 2026, a total of 10 patients were enrolled, with a median age at diagnosis of 34 years (range 17–62). Five patients were male. At diagnosis, the median platelet count was 13 × 10?/L (range 1–30), and the median disease duration since ITP diagnosis was 2.5 years. Anti-platelet glycoprotein antibodies were negative in 80% (8/10) and positive in 20% (2/10). The median serum TPO level was 84.86 pg/mL (range, 7.45–2000). The median number of prior therapy lines was 4 (range 2–6). All patients had received corticosteroids, 4 (40%) had received IVIg, and all 10 (100%) had received at least one TPO receptor agonist: eltrombopag in 2 (20%), avatrombopag in 6 (60%), romiplostim in 7 (70%), and hetrombopag in 5 (50%). Additionally, 1 (10%) had prior rituximab, 4 (40%) prior cyclosporine, and 1 (10%) prior splenectomy. Among the 10 patients, 3 received orelabrutinib plus corticosteroids, 5 received orelabrutinib plus a TPO receptor agonist (eltrombopag [n=1], romiplostim [n=1], and avatrombopag [n=3]), and 2 received orelabrutinib plus cyclosporine. After treatment, the OR rate was 70% and CR rate was 60%. Specifically, 6 patients achieved CR, 1 achieved R, and 3 achieved NR. Among the 7 patients who achieved at least R, 6 responded within one week, and 1 responded within one month. In responding patients, the median maximum platelet count was 249 × 10?/L (range: 161–652).The median time to response (TTR) was 7 days (range: 1–27). Among 10 patients, median follow-up was 2.0 months (range, 0.5–20.3). Three patients with follow-up ≥6 months maintained response on orelabrutinib without discontinuation, thus meeting the predefined sustained-response criterion. No patient relapsed during the available follow-up. Adverse events (AEs) were grade 1–2 in 3 patients and grade 3 in 1 patient.These included thrombosis (30%), elevated creatinine and/or uric acid (20%), mild hepatic dysfunction (10%), and arthralgia (10%).

Conclusions

In the real-world setting, the orelabrutinib-based regimen exhibited favorable efficacy and a rapid onset of action in treating refractory ITP, highlighting its potential as a promising therapeutic approach for patients with refractory ITP.

Wanying Lin: No relevant conflicts of interest to declare.